Hit enter to search or ESC to close

Category: Investor Announcement

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 20 February 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), ...

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

– ATH434-201 Trial on Track to Complete in November 2024 – – Top-Line Data Expected in January 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 6 February 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an ...

Alterity Therapeutics Successfully Completes Securities Purchase Plan (SPP)

Not for release to US wire services or distribution in the United States MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 2 February 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Securities Purchase Plan (SPP) has been ...

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 29 January 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the ShareCafe Hidden Gems webinar on the following dates/times: AUSTRALIA PARTICIPANTS: ...

Appendix 4C – Q2 FY24 Quarterly Cash Flow Report

Highlights MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 January 2024, Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 December 2023 (Q2 ...

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 December 2023:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details ...

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease

– ATH434 improved motor performance and general function – – Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 December 2023:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for ...